Phenotypic changes of lymphocytes in patients with systemic lupus erythematosus who are in longterm remission after B cell depletion therapy with rituximab

Journal of Rheumatology

Volumn 38, Issue 4, 2011, Pages 633-641

  Iwata, Shigeru ^a   Saito, Kazuyoshi ^a   Tokunaga, Mikiko ^a   Yamaoka, Kunihiro ^a   Nawata, Masao ^a   Yukawa, Sonosuke ^a   Hanami, Kentaro ^a   Fukuyo, Shunsuke ^a   Miyagawa, Ippei ^a   Kubo, Satoshi ^a   Tanaka, Yoshiya ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

B cell depletion therapy; Rituximab; Systemic lupus erythematosus

Indexed keywords

AZATHIOPRINE; B7 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; MIZORIBINE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB;

ADOLESCENT; ADULT; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; B LYMPHOCYTE DIFFERENTIATION; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG INTERMITTENT THERAPY; DRUG PULSE THERAPY; DRUG RESPONSE; FEMALE; HUMAN; IMMUNOADSORPTION; LONGITUDINAL STUDY; LYMPHOCYTE COUNT; MALE; MEMORY CELL; MEMORY T LYMPHOCYTE; PHENOTYPE; PLASMAPHERESIS; PRIORITY JOURNAL; RELAPSE; REMISSION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; UPREGULATION;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD; B-LYMPHOCYTES; CELL DIFFERENTIATION; COHORT STUDIES; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE DEPLETION; MALE; PHENOTYPE; RECURRENCE; REMISSION INDUCTION; T-LYMPHOCYTES; YOUNG ADULT;

EID: 79953314262     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.100729     Document Type: Article

References (27)

1. Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004;50:2580-9. (Pubitemid 39062719)
2. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002;46:2673-7. (Pubitemid 36118931)
3. Rastetter W, Molina A, White CA. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases. Annu Rev Med 2004;55:477-503. (Pubitemid 38316738)
4. Anolik J, Sanz I, Looney RJ. B cell depletion therapy in systemic lupus erythematosus. Curr Rheumatol Rep 2003;5:350-6.
5. Tanaka Y, Yamamoto K, Takeuchi T, Nishimoto N, Miyasaka N, Sumida T, et al. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol 2007;17:191-7. (Pubitemid 46929903)
6. Tokunaga M, Fujii K, Saito K, Nakayamada S, Tsujimura S, Nawata M, et al. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology 2005;44:176-82. (Pubitemid 40277398)
7. Tokunaga M, Saito K, Kawabata D, Imura Y, Fujii T, Nakayamada S, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 2007;66:470-5. (Pubitemid 46580466)
8. Lu TY, Ng KP, Cambridge G, Leandro MJ, Edwards JC, Ehrenstein M, et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum 2009;61:482-7.
9. Anolik JH, Barnard J, Cappione A, Pugh-Bernard AE, Felgar RE, Looney RJ, et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004;50:3580-90. (Pubitemid 39488683)
10. Wei C, Anolik J, Cappione A, Zheng B, Pugh-Bernard A, Brooks J, et al. A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus. J Immunol 2007;178:6624-33. (Pubitemid 46717447)
11. Cappione A, Anolik JH, Pugh-Bernard A, Barnard J, Dutcher P, Silverman G, et al. Germinal center exclusion of autoreactive B cells is defective in human systemic lupus erythematosus. J Clin Invest 2005;115:3205-16. (Pubitemid 41567585)
12. Jacobi AM, Odendahl M, Reiter K, Bruns A, Burmester GR, Radbruch A, et al. Correlation between circulating CD27 high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2003;48:1332-42. (Pubitemid 36554532)
13. Anolik JH, Barnard J, Owen T, Zheng B, Kemshetti S, Looney RJ, et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum 2007;56:3044-56. (Pubitemid 47502752)
14. Desai-Mehta A, Lu L, Ramsey-Goldman R, Datta SK. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 1996;97:2063-73. (Pubitemid 26143961)
15. Grammar AC, Slota R, Fischer R, Gur H, Girschick H, Yarboro C, et al. Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J Clin Invest 2003;112:1506-20. (Pubitemid 38056277)
16. Harris DP, Haynes L, Sayles PC, Duso DK, Eaton SM, Lepak NM, et al. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol 2000;1:475-82.
17. Skok J, Poudrier J, Gray D. Dendritic cell-derived IL-12 promotes B cell induction of Th2 differentiation: a feedback regulation of Th1 development. J Immunol 1999;163:4284-91. (Pubitemid 29474494)
18. Vallerskog T, Gunnarsson I, Widhe M, Risselada A, Klareskog L, van Vollenhoven R, et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol 2007;122:62-74. (Pubitemid 46026695)
19. Sfikakis PP, Souliotis VL, Fragiadaki KG, Moutsopoulos HM, Boletis JN, Theofilopoulos AN. Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin Immunol 2007;123:66-73. (Pubitemid 46401511)
20. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7. (Pubitemid 13221242)
21. Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993;86:447-58. (Pubitemid 23223653)
22. Bencivelli W, Vitali C, Isenberg DA, Smolen JS, Snaith ML, Sciuto M, et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. III. Development of a computerised clinical chart and its application to the comparison of different indices of disease activity. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol 1992;10:549-54.
23. Morimoto C, Steinberg AD, Letvin NL, Hagan M, Takeuchi T, Daley J, et al. A defect of immunoregulatory T cell subsets in systemic lupus erythematosus patients demonstrated with anti-2H4 antibody. J Clin Invest 1987;79:762-8. (Pubitemid 17050900)
24. Sato K, Miyasaka N, Yamaoka K, Okuda M, Yata J, Nishioka K. Quantitative defect of CD4+2H4+ cells in systemic lupus erythematosus and Sjögren's syndrome. Arthritis Rheum 1987;30:1407-11. (Pubitemid 18051912)
25. Raziuddin S, Nur MA, Alwabel AA. Selective loss of the CD4+ inducers of suppressor T cell subsets (2H4+) in active systemic lupus erythematosus. J Rheumatol 1989;16:1315-9. (Pubitemid 19276949)
26. Tanaka S, Matsuyama T, Steinberg AD, Schlossman SF, Morimoto C. Antilymphocyte antibodies against CD4+2H4+ cell populations in patients with systemic lupus erythematosus. Arthritis Rheum 1989;32:398-405. (Pubitemid 19118665)
27. Mimura T, Fernsten P, Jarjour W, Winfield JB. Autoantibodies specific for different isoforms of CD45 in systemic lupus erythematosus. J Exp Med 1990;172:653-6. (Pubitemid 20248408)